Patent Issued for Consensus prostate antigens, nucleic acid molecule encoding the same and vaccine and uses comprising the same (USPTO 11980659).
In: Cancer Weekly, 2024-06-04, S. 1831-1831
serialPeriodical
Zugriff:
A patent has been issued for consensus prostate antigens, nucleic acid molecules encoding them, and vaccines and uses comprising them. The patent discusses the development of immune therapeutic approaches for prostate cancer, specifically focusing on DNA vaccines. The inventors highlight the advantages of DNA vaccines and recent technological advances in their engineering and delivery systems. The patent includes nucleic acid molecules encoding specific proteins used in the treatment of prostate cancer, as well as methods of administering these molecules and compositions containing them. This information may be valuable for researchers studying prostate cancer and exploring potential treatments. [Extracted from the article]
Copyright of Cancer Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Patent Issued for Consensus prostate antigens, nucleic acid molecule encoding the same and vaccine and uses comprising the same (USPTO 11980659).
|
---|---|
Zeitschrift: | Cancer Weekly, 2024-06-04, S. 1831-1831 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1071-7218 (print) |
Schlagwort: |
|
Sonstiges: |
|